title: A new type of biphasic calcium phosphate cement as a gentamicin carrier for osteomyelitis.
abstract: Osteomyelitis therapy is a long-term and inconvenient procedure for a patient. Antibiotic-loaded bone cements are both a complementary and alternative treatment option to intravenous antibiotic therapy for the treatment of osteomyelitis. In the current study, the biphasic calcium phosphate cement (CPC), called α -TCP/HAP ( α -tricalcium phosphate/hydroxyapatite) biphasic cement, was prepared as an antibiotics carrier for osteomyelitis. The developed biphasic cement with a microstructure of α -TCP surrounding the HAP has a fast setting time which will fulfill the clinical demand. The X-ray diffraction and Fourier transform infrared spectrometry analyses showed the final phase to be HAP, the basic bone mineral, after setting for a period of time. Scanning electron microscopy revealed a porous structure with particle sizes of a few micrometers. The addition of gentamicin in α -TCP/HAP would delay the transition of α -TCP but would not change the final-phase HAP. The gentamicin-loaded α -TCP/HAP supplies high doses of the antibiotic during the initial 24 hours when they are soaked in phosphate buffer solution (PBS). Thereafter, a slower drug release is produced, supplying minimum inhibitory concentration until the end of the experiment (30 days). Studies of growth inhibition of Staphylococcus aureus and Pseudomonas aeruginosa in culture indicated that gentamicin released after 30 days from α -TCP/HAP biphasic cement retained antibacterial activity.
authors: Division of Medical Engineering Research, National Health Research Institutes, Miaoli county 350, Taiwan ; Institute of Biomedical Engineering, National Taiwan University, Taipei 100, Taiwan ; Institute of Biomedical Engineering and Material Science, Central Taiwan University of Science and Technology, Taichung 406, Taiwan.
authors: Wen-Yu
authors: WY
authors: Su
authors: Yu-Chun
authors: YC
authors: Chen
authors: Feng-Huei
authors: FH
authors: Lin
references: Biomaterials. 2005 Sep;26(25):5251-8
references: 15792552
references: J Arthroplasty. 2005 Dec;20(8):1055-9
references: 16376263
references: J Control Release. 2006 Jun 28;113(2):102-10
references: 16740332
references: J Antimicrob Chemother. 2006 Feb;57(2):301-5
references: 16361330
references: Vet Surg. 2011 Jul;40(5):563-70
references: 21545461
references: Orthopedics. 1994 May;17(5):415-6
references: 8036185
references: J Biomed Mater Res B Appl Biomater. 2010 Apr;93(1):51-8
references: 20024966
references: J Biomed Mater Res. 2002 Mar 5;59(3):490-8
references: 11774307
references: J Orthop Sci. 2007 May;12(3):281-8
references: 17530381
references: J Arthroplasty. 1996 Dec;11(8):939-44
references: 8986572
references: Clin Orthop Relat Res. 1993 Oct;(295):112-8
references: 8403634
references: Drugs. 2000 Jun;59(6):1223-32
references: 10882159
references: Biomaterials. 2004 Aug;25(18):4287-95
references: 15046919
references: Biomaterials. 2006 Aug;27(23):4239-49
references: 16620958
references: Semin Plast Surg. 2009 May;23(2):100-7
references: 20567732
references: Biomaterials. 2010 Sep;31(25):6363-77
references: 20542556
references: J Dent Res. 1997 Apr;76(4):905-12
references: 9126187
references: J Pharm Sci. 1997 May;86(5):565-72
references: 9145380
references: Clin Orthop Relat Res. 1997 Aug;(341):206-14
references: 9269175
references: Acta Biomater. 2012 Apr;8(4):1401-21
references: 22127225
references: Drug Discov Today. 2010 Jul;15(13-14):547-52
references: 20546919
references: Clin Orthop Relat Res. 2005 Aug;(437):105-10
references: 16056034
references: BMC Musculoskelet Disord. 2006 Feb 26;7:18
references: 16504140
references: ISRN Orthop. 2011 Aug 07;2011:290851
references: 24977058
references: Adv Drug Deliv Rev. 2012 Sep;64(12):1090-110
references: 22310160